HF Advisory Group LLC Raises Stock Position in Cencora, Inc. (NYSE:COR)

HF Advisory Group LLC raised its stake in shares of Cencora, Inc. (NYSE:COR) by 10.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 4,443 shares of the company’s stock after buying an additional 412 shares during the quarter. HF Advisory Group LLC’s holdings in Cencora were worth $1,000,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of COR. Kingswood Wealth Advisors LLC bought a new stake in shares of Cencora in the second quarter worth $655,000. TD Asset Management Inc purchased a new position in Cencora in the first quarter worth about $95,313,000. LSV Asset Management purchased a new position in Cencora in the first quarter worth about $3,579,000. Lake Street Advisors Group LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $836,000. Finally, Leith Wheeler Investment Counsel Ltd. purchased a new stake in shares of Cencora during the 1st quarter valued at about $12,832,000. 97.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Robert W. Baird dropped their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Finally, Evercore ISI cut their price target on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $259.44.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.0 %

Shares of COR stock opened at $233.93 on Wednesday. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The stock has a fifty day simple moving average of $231.39 and a two-hundred day simple moving average of $230.54. The firm has a market capitalization of $46.10 billion, a PE ratio of 25.40, a PEG ratio of 1.49 and a beta of 0.44. Cencora, Inc. has a 52-week low of $191.11 and a 52-week high of $247.66.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.